A Unblinded Study of TAK-438 (20 mg) for Prevention of Recurrence of Gastric or Duodenal Ulcer During Long-Term Non-Steroid Anti-Inflammatory Drug (NSAID) Therapy

Trial Profile

A Unblinded Study of TAK-438 (20 mg) for Prevention of Recurrence of Gastric or Duodenal Ulcer During Long-Term Non-Steroid Anti-Inflammatory Drug (NSAID) Therapy

Completed
Phase of Trial: Phase III

Latest Information Update: 23 May 2016

At a glance

  • Drugs Vonoprazan (Primary)
  • Indications Duodenal ulcer; Gastric ulcer
  • Focus Adverse reactions; Registrational
  • Sponsors Takeda
  • Most Recent Events

    • 07 Feb 2014 According to ClinicalTrials.gov.Status changed from recruiting to completed.
    • 25 Jul 2012 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
    • 13 Apr 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top